EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti‐tumoral microenvironment: Novel role of trained immunity

Aline Atallah iD, Arielle Grossman iD, Richard W Nauman, Jean-François Paré, Adam Khan, D Robert Siemens, Tiziana Cotechini iD, Charles H Graham iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Aline Atallah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Tumor Microenvironment, BCG Vaccine, Immunotherapy. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Southeastern Ontario Academic Medical Organization, Canadian Institutes of Health Research Frederick Banting and Charles Best Canada Graduate Scholarship-Master's.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment for higher‐risk non‐muscle invasive bladder cancer (NMIBC) involves intravesical immunotherapy with Bacillus Calmette Guérin (BCG); however, disease recurrence and progression occur frequently. Systemic immunity is critical for successful cancer immunotherapy; thus, recurrence of NMIBC may be due to suboptimal systemic activation of anti‐tumor immunity after local immunotherapy. We previously reported that systemically acquired trained immunity (a form of innate immune memory) in circulating monocytes is associated with increased time‐to‐recurrence in patients with NMIBC treated with BCG. Herein, we used a mouse model of NMIBC to compare the effects of intravesical versus intravenous (systemic) BCG immunotherapy on the local and peripheral immune microenvironments. We also assessed whether BCG‐induced trained immunity modulates anti‐tumor immune responses. Compared with intravesical BCG, which led to a tumor‐promoting immune microenvironment, intravenous BCG resulted in an anti‐tumoral bladder microenvironment characterized by increased proportions of cytotoxic T lymphocytes (CTLs), and decreased proportions of myeloid‐derived suppressor cells. Polarization toward anti‐tumoral immunity occurred in draining lymph nodes, spleen, and bone marrow following intravenous versus intravesical BCG treatment. Pre‐treatment with intravesical BCG was associated with increased rate of tumor growth compared with intravenous BCG pre‐treatment. Trained immunity contributed to remodeling of the tumor immune microenvironment, as co‐instillation of BCG‐trained macrophages with ovalbumin‐expressing bladder tumor cells increased the proportion of tumor‐specific CTLs. Furthermore, BCG‐trained dendritic cells exhibited enhanced antigen uptake and presentation and promoted CTL proliferation. Our data support the concept that systemic immune activation promotes anti‐tumor responses, and that BCG‐induced trained immunity is important in driving anti‐tumor adaptive immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsTumor MicroenvironmentBCG VaccineImmunotherapyAnimalsMiceFemaleAdministration, IntravesicalMice, Inbred C57BLT-Lymphocytes, CytotoxicHumansDisease Models, AnimalImmunity, InnateCell Line, TumorImmunologic MemoryMyeloid-Derived Suppressor CellsTrained Immunity

Stichwörter der Autor:innen

BCGbladder cancerimmune microenvironmentsystemic immunitytrained immunity

Substanzen

BCG Vaccine

Autor:innen und Institutionen

  • Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
  • Department of Urology, Queen's University, Kingston, Ontario, Canada.

ORCID-Profile: Aline Atallah, Arielle Grossman, Tiziana Cotechini, Charles H Graham

Förderung

  • CIHR
  • Southeastern Ontario Academic Medical Organization
  • Canadian Institutes of Health Research Frederick Banting and Charles Best Canada Graduate Scholarship-Master's
  • Ontario Graduate Scholarship
  • Natural Science and Engineering Research Council of Canada Alexander G. Bell Canada Graduate Scholarship
  • Canadian Institutes of Health Research

Zitieren

APA

Atallah, A., Grossman, A., Nauman, R. W., Paré, J. F., Khan, A., Siemens, D. R., Cotechini, T., & Graham, C. H. (2024). Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti‐tumoral microenvironment: Novel role of trained immunity. International Journal of Cancer. https://doi.org/10.1002/ijc.34897

Vancouver

Atallah A, Grossman A, Nauman RW, Paré JF, Khan A, Siemens DR, et al. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti‐tumoral microenvironment: Novel role of trained immunity. International Journal of Cancer. 2024. doi:10.1002/ijc.34897

BibTeX
@article{Atallah2024,
  author = {Atallah, Aline and Grossman, Arielle and Nauman, Richard W and Paré, Jean-François and Khan, Adam and Siemens, D Robert and Cotechini, Tiziana and Graham, Charles H},
  title = {Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti‐tumoral microenvironment: Novel role of trained immunity},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34897}
}
Kostenlos starten →